D'Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune checkpoint inhibitor) in non-small cell lung cancer (NSCLC). The research was published in the New England Journal of Medicine (NEJM), one of the most important scientific publications in the medical field, and included Dr. Milena Perez Mak, IDOR researcher and clinical oncologist at the São Paulo State Cancer Institute (Icesp). 

Published in the scientific journal “Religion, Brain & Behavior”, a study led by the D’Or Institute for Research and Education (IDOR) evaluated and mapped the perceptions of over a thousand spectators participating in the Festival of the Nine Emperor Gods, a celebration that gathers approximately one million people in several Asian countries and has predominantly religious significance. In these events, self-inflicted violence is normalized by a small portion of its participants. The research aimed to map the audience’s reactions to these rituals, seeking to understand the social effects of this cultural event. 

Acute Myeloid Leukemia (AML) is a cancer type that originates in the bone marrow. Despite being considered a rare disease, it is the most common type of acute leukemia and progresses rapidly, necessitating immediate treatment. While many advancements have been made in the disease’s treatment, these resources are not fully accessible in underdeveloped countries. This situation has prompted Latin American scientists to seek a comprehensive understanding of AML on their continent, with a primary focus on the therapies and diagnostic methods available for this population.

The school will provide a set of intensive courses for postgraduate students and early-career researchers on the recent developments in the economics of technological change and in ST&I policy studies.  Registrations are due on January 26, 2024.

According to the World Health Organization (WHO), the number of snakebite victims worldwide is between 4.5 million and 5.4 million per year, with 1.8 million-2.7 million developing clinical illness, and 81,000-138,000 dying from complications. High-risk groups include agricultural workers, herders, fishermen, hunters, working children, and people living in poorly constructed houses. n the Brazilian study, 45% of the victims stated their occupation to be agricultural workers, followed by school students, with 16%. Better data will help improve research and antivenom distribution.